Walleye Capital’s ADMA Biologics ADMA Stock Holding History

Walleye Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$245K	Buy	+27,158	New	+$429K	﹤0.01%	3206
2024 Q4	–	Sell	-73,568	Closed	-$1.47M	–	4760
2024 Q3	$1.47M	Buy	73,568 +25,442	+53%	+$396K	﹤0.01%	2251
2024 Q2	$538K	Buy	48,126 +30,564	+174%	+$256K	﹤0.01%	3445
2024 Q1	$116K	Buy	+17,562	New	+$96K	﹤0.01%	4313
2023 Q4	–	Sell	-926,745	Closed	-$3.32M	–	4879
2023 Q3	$3.32M	Buy	+926,745	New	+$3.57M	0.01%	1341
2023 Q1	–	Sell	-44,323	Closed	-$172K	–	3874
2022 Q4	$172K	Buy	+44,323	New	+$137K	﹤0.01%	2132

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Walleye Capital's ADMA Position: Q1 2026 in Review

Walleye Capital opened a new position in ADMA Biologics (ADMA) in Q1 2026: 27,158 shares worth $245K. The stake represents ﹤0.01% of the portfolio and ranks #3206 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ADMA as recently as Q3 2024.

Walleye Capital first reported a position in ADMA in Q4 2022 and has held it in 6 quarters since. The position peaked at $3.32M in Q3 2023. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Walleye Capital held 27,158 shares of ADMA Biologics worth $245K as of Q1 2026.
ADMA Biologics was a new Walleye Capital position in Q1 2026.
ADMA Biologics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3206 holding.
Walleye Capital first reported a position in ADMA Biologics in Q4 2022 and has held it in 6 quarters since.
Walleye Capital's ADMA Biologics position peaked at $3.32M in Q3 2023.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.